Brad Clibborn is a portfolio manager at Bennelong Australian Equity Partners. The Sydney-based boutique fund oversees $6 billion in assets.

Which stock in your fund is the most undervalued by the market?
Australian biotech company CSL has been a strong performer for us over a long period of time. However, in the past four to five years, the stock has gone sideways. Many other growth stocks have re-rated.